{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:48:30Z","timestamp":1794577710138,"version":"4.9.1"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of ketamine for depression has increased rapidly in the past decades. Ketamine is often prescribed as an add-on to other drugs used in psychiatric patients, but clear information on drug-drug interactions is lacking. With this review, we aim to provide an overview of the pharmacodynamic interactions between ketamine and mood stabilizers, benzodiazepines, monoamine oxidase-inhibitors, antipsychotics, and psychostimulants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MEDLINE and Web of Science were searched.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-four studies were included. For lithium, no significant interactions with ketamine were reported. Two out of 5 studies on lamotrigine indicated that the effects of ketamine were attenuated. Benzodiazepines were repeatedly shown to reduce the duration of ketamine\u2019s antidepressant effect. For the monoamine oxidase-inhibitor tranylcypromine, case reports showed no relevant changes in vital signs during concurrent S-ketamine use. One paper indicated an interaction between ketamine and haloperidol, 2 other studies did not. Four papers investigated risperidone, including 3 neuroimaging studies showing an attenuating effect of risperidone on ketamine-induced brain perfusion changes. Clozapine significantly blunted ketamine-induced positive symptoms in patients with schizophrenia but not in healthy participants. One paper reported no effect of olanzapine on ketamine\u2019s acute psychotomimetic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current literature shows that benzodiazepines and probably lamotrigine reduce ketamine\u2019s treatment outcome, which should be taken into account when considering ketamine treatment. There is evidence for an interaction between ketamine and clozapine, haloperidol, and risperidone. Due to small sample sizes, different subject groups and various outcome parameters, the evidence is of low quality. More studies are needed to provide insight into pharmacodynamic interactions with ketamine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijnp\/pyab039","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T23:16:00Z","timestamp":1624490160000},"page":"808-831","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9075-4804","authenticated-orcid":false,"given":"Jolien K E","family":"Veraart","sequence":"first","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, the Netherlands"},{"name":"PsyQ Haaglanden, Parnassia Psychiatric Institute, The Hague, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne Y","family":"Smith-Apeldoorn","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris M","family":"Bakker","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berber A E","family":"Visser","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Kamphuis","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Schoevers","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, the Netherlands"},{"name":"University of Groningen, Research School of Behavioural and Cognitive Neurosciences (BCN), Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J","family":"Touw","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"2021102310543296800_CIT0001","first-page":"566","article-title":"Prefrontal connectivity and glutamate transmission: relevance to depression pathophysiology and ketamine treatment","volume":"2","author":"Abdallah","year":"2017","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"2021102310543296800_CIT0002"},{"key":"2021102310543296800_CIT0004","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archpsyc.57.3.270","article-title":"Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists","volume":"57","author":"Anand","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"2021102310543296800_CIT0005","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.1016\/j.euroneuro.2018.11.592","article-title":"Concurrent benzodiazepines undermine the antidepressant effect of ketamine","volume":"29","author":"Andrashko","year":"2019","journal-title":"Eur Neuropsychopharmacol"},{"key":"2021102310543296800_CIT0006","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jad.2018.02.056","article-title":"Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial","volume":"235","author":"Arabzadeh","year":"2018","journal-title":"J Affect Disord"},{"key":"2021102310543296800_CIT0007","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.euroneuro.2015.07.021","article-title":"Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: a report of two cases","volume":"25","author":"Bartova","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"2021102310543296800_CIT0008","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3163\/1536-5050.104.3.014","article-title":"De-duplication of database search results for systematic reviews in EndNote","volume":"104","author":"Bramer","year":"2016","journal-title":"J Med Libr Assoc"},{"key":"2021102310543296800_CIT0009","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/s41386-019-0365-0","article-title":"Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial","volume":"44","author":"Costi","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"2021102310543296800_CIT0010","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1001\/archgenpsychiatry.2007.37","article-title":"Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study","volume":"65","author":"Deakin","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"2021102310543296800_CIT0011","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0952-8180(90)90078-H","article-title":"Ketamine induction and monoamine oxidase inhibitors","volume":"2","author":"Doyle","year":"1990","journal-title":"J Clin Anesth"},{"key":"2021102310543296800_CIT0012","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1124\/jpet.112.201665","article-title":"Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents","volume":"345","author":"Doyle","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"2021102310543296800_CIT0013","first-page":"298","article-title":"Safety and efficacy of esketamine nasal spray in a depressed patient who was being treated with tranylcypromine: a case report","volume":"44","author":"Dunner","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"2021102310543296800_CIT0014","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/bja\/82.4.596","article-title":"Effects of diazepam and ketamine administered individually or in combination on regional rates of glucose utilization in rat brain","volume":"82","author":"Eintrei","year":"1999","journal-title":"Br J Anaesth"},{"key":"2021102310543296800_CIT0015","author":"EMA","year":"2019"},{"key":"2021102310543296800_CIT0016","author":"FDA","year":"2019"},{"key":"2021102310543296800_CIT0017","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2165\/00003495-199040050-00007","article-title":"Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia","volume":"40","author":"Fitton","year":"1990","journal-title":"Drugs"},{"key":"2021102310543296800_CIT0018","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1177\/0004867415590631","article-title":"Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression","volume":"49","author":"Ford","year":"2015","journal-title":"Aust N Z J Psychiatry"},{"key":"2021102310543296800_CIT0019","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0000000000000316","article-title":"Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development","volume":"35","author":"Frye","year":"2015","journal-title":"J Clin Psychopharmacol"},{"key":"2021102310543296800_CIT0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/0269881109104845","article-title":"NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test","volume":"24","author":"Ghasemi","year":"2010","journal-title":"J Psychopharmacol"},{"key":"2021102310543296800_CIT0021","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2147\/NDT.S117146","article-title":"Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies","volume":"12","author":"Han","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2021102310543296800_CIT0022","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1017\/S0033291715002159","article-title":"Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study","volume":"46","author":"Hu","year":"2016","journal-title":"Psychol Med"},{"key":"2021102310543296800_CIT0023","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/HRP.0000000000000179","article-title":"Ketamine-associated brain changes: a review of the neuroimaging literature","volume":"26","author":"Ionescu","year":"2018","journal-title":"Harv Rev Psychiatry"},{"key":"2021102310543296800_CIT0024","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/BF03012584","article-title":"Inhibition by diazepam of ketamine-induced hyperlocomotion and dopamine turnover in mice","volume":"45","author":"Irifune","year":"1998","journal-title":"Can J Anaesth"},{"key":"2021102310543296800_CIT0025","author":"JBI","year":"2020"},{"key":"2021102310543296800_CIT0026","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1007\/s00213-015-3951-9","article-title":"Ketamine induces a robust whole-brain connectivity pattern that can be differentially modulated by drugs of different mechanism and clinical profile","volume":"232","author":"Joules","year":"2015","journal-title":"Psychopharmacology"},{"key":"2021102310543296800_CIT0027","first-page":"1","article-title":"Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge and expert guidance","author":"Kasper","year":"2020","journal-title":"World J Biol Psychiatry"},{"key":"2021102310543296800_CIT0028","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol Med"},{"key":"2021102310543296800_CIT0029","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14656566.2019.1683161","article-title":"Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder","volume":"21","author":"Kryst","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"2021102310543296800_CIT0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"2021102310543296800_CIT0031","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002130050503","article-title":"Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans","volume":"135","author":"Krystal","year":"1998","journal-title":"Psychopharmacology"},{"key":"2021102310543296800_CIT0032","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s002130051049","article-title":"Interactive effects of subanesthetic ketamine and haloperidol in healthy humans","volume":"145","author":"Krystal","year":"1999","journal-title":"Psychopharmacology"},{"key":"2021102310543296800_CIT0033","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"2021102310543296800_CIT0034","first-page":"310","article-title":"Blockade of ketamine-induced psychosis with olanzapine","volume":"36","author":"Lahti","year":"1999","journal-title":"Schizophr Res"},{"key":"2021102310543296800_CIT0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/7854_2010_60","article-title":"Eye tracking dysfunction in schizophrenia: characterization and pathophysiology","volume":"4","author":"Levy","year":"2010","journal-title":"Curr Top Behav Neurosci"},{"key":"2021102310543296800_CIT0036","first-page":"76","article-title":"Clozapine blockade of ketamine effects in healthy subjects","volume":"41","author":"Lipschitz","year":"1997","journal-title":"Biol Psychiatry"},{"key":"2021102310543296800_CIT0037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/2045125316675578","article-title":"Use of repeated intravenous ketamine therapy in treatment-resistant bipolar depression with suicidal behaviour: a case report from Spain","volume":"7","author":"L\u00f3pez-D\u00edaz","year":"2017","journal-title":"Ther Adv Psychopharmacol"},{"key":"2021102310543296800_CIT0038","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1192\/bjp.2019.102","article-title":"Off-label use of ketamine for treatment-resistant depression in clinical practice: European perspective","volume":"215","author":"L\u00f3pez-D\u00edaz","year":"2019","journal-title":"Br J Psychiatry"},{"key":"2021102310543296800_CIT0039","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0004867420979353","article-title":"The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders","volume":"55","author":"Malhi","year":"2021","journal-title":"Aust N Z J Psychiatry"},{"key":"2021102310543296800_CIT0040","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0006-3223(96)00546-X","article-title":"Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine","volume":"42","author":"Malhotra","year":"1997","journal-title":"Biol Psychiatry"},{"key":"2021102310543296800_CIT0041","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S1461145709000169","article-title":"Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial","volume":"13","author":"Mathew","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021102310543296800_CIT0042","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-42925-0","volume-title":"Ketamine for treatment-resistant depression. The first decade of progress","author":"Mathew","year":"2016"},{"key":"2021102310543296800_CIT0043","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11126-020-09830-6","article-title":"Effectiveness and safety of ketamine for unipolar depression: a systematic review","volume":"91","author":"Memon","year":"2020","journal-title":"Psychiatr Q"},{"key":"2021102310543296800_CIT0044","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0304-3940(99)00688-6","article-title":"Ketamine stereoselectively inhibits rat dopamine transporter","volume":"274","author":"Nishimura","year":"1999","journal-title":"Neurosci Lett"},{"key":"2021102310543296800_CIT0045","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1017\/S1461145708009814","article-title":"Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude","volume":"12","author":"Oranje","year":"2009","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021102310543296800_CIT0046","doi-asserted-by":"crossref","first-page":"19r12859","DOI":"10.4088\/JCP.19r12859","article-title":"Maintaining rapid antidepressant effects following ketamine infusion: a major unmet need","volume":"81","author":"Papakostas","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"2021102310543296800_CIT0047","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1001\/jama.285.10.1299","article-title":"Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial","volume":"285","author":"Sackeim","year":"2001","journal-title":"Jama"},{"key":"2021102310543296800_CIT0048","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1038\/tp.2013.109","article-title":"The effects of ketamine and risperidone on eye movement control in healthy volunteers","volume":"3","author":"Schmechtig","year":"2013","journal-title":"Transl Psychiatry"},{"key":"2021102310543296800_CIT0049","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jcph.122","article-title":"Repeated S-ketamine infusions in therapy resistant depression: a case series","volume":"53","author":"Segmiller","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"2021102310543296800_CIT0050","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1007\/s00213-015-4021-z","article-title":"Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects","volume":"232","author":"Shcherbinin","year":"2015","journal-title":"Psychopharmacology"},{"key":"2021102310543296800_CIT0051","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.156.11.1744","article-title":"Double-blind study of clozapine dose response in chronic schizophrenia","volume":"156","author":"Simpson","year":"1999","journal-title":"Am J Psychiatry"},{"key":"2021102310543296800_CIT0052","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0006-3223(97)00485-X","article-title":"Prefrontal and cerebellar abnormalities in major depression: evidence from oculomotor studies","volume":"43","author":"Sweeney","year":"1998","journal-title":"Biol Psychiatry"},{"key":"2021102310543296800_CIT0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0197-0186(03)00104-9","article-title":"Stereoselective effects of ketamine on dopamine, serotonin and noradrenaline release and uptake in rat brain slices","volume":"44","author":"Tso","year":"2004","journal-title":"Neurochem Int"},{"key":"2021102310543296800_CIT0054","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1176\/ajp.153.12.1579","article-title":"Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges","volume":"153","author":"VanderZwaag","year":"1996","journal-title":"Am J Psychiatry"},{"key":"2021102310543296800_CIT0055","first-page":"27","article-title":"Effect of clozapine and ketanserin on S-ketamine-induced brain activation and psychotic symptoms in healthy humans","volume":"15","author":"Vollenweider","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"2021102310543296800_CIT0056","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/jama.2017.10697","article-title":"Considerations on the off-label use of ketamine as a treatment for mood disorders","volume":"318","author":"Wilkinson","year":"2017","journal-title":"JAMA"},{"key":"2021102310543296800_CIT0057","doi-asserted-by":"crossref","first-page":"858251","DOI":"10.1155\/2015\/858251","article-title":"Lithium and valproate levels do not correlate with ketamine\u2019s antidepressant efficacy in treatment-resistant bipolar depression","volume":"2015","author":"Xu","year":"2015","journal-title":"Neural Plast"},{"key":"2021102310543296800_CIT0058","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","article-title":"Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression","volume":"106","author":"Zheng","year":"2018","journal-title":"J Psychiatr Res"},{"key":"2021102310543296800_CIT0059","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/JCP.0b013e3182856865","article-title":"Urgent ketamine infusion rapidly eliminated suicidal ideation for a patient with major depressive disorder: a case report","volume":"33","author":"Zigman","year":"2013","journal-title":"J Clin Psychopharmacol"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyab039\/39459639\/pyab039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/24\/10\/808\/40830449\/pyab039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/24\/10\/808\/40830449\/pyab039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T04:47:56Z","timestamp":1672548476000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/24\/10\/808\/6309481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,6,25]]},"published-print":{"date-parts":[[2021,10,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyab039","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,6,25]]}}}